Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF)
(the "
Company" or "
Claritas")
today announced that the journal Scientific Reports,
has published a peer-reviewed article reporting that R-107,
the Company’s nitric oxide-releasing compound, effectively
preserved multi-organ function in a sheep model of sepsis. These
significantly positive data suggest that R-107 may be a potentially
revolutionary new treatment for sepsis, a life-threatening
condition, and the most frequent cause of death in intensive care
units due to multiple organ failure.
Highlights
- R-107 was evaluated in a
controlled large animal (sheep) model of sepsis, with significantly
positive results. These results unequivocally demonstrated that
R-107 reduced mortality, and provide important support for the
Company’s development of R-107 for COVID-19 related
sepsis.
- Sepsis is
a potentially life-threatening condition that occurs when the
body's response to an infection damages its own tissues and organs,
and is the leading cause of death in
COVID-19 patients, with a mortality rate of 30% -
40%.1
- The worldwide market for
treatment of sepsis was valued at more than
USD $600 million in 2020, and is projected to grow to USD $1.6
Billion by 2031.2
-
Following completion of the Phase 1 clinical study of R-107
in Q1 2022, Claritas will apply for U.S.
governmental grant funding from the Biomedical Advanced Research
Development Authority (“BARDA”), an agency within the U.S.
Department of Health and Human Services, to fund the Phase 2 and
Phase 3 clinical studies of R-107 in COVID-related
sepsis.
Positive Results with R-107 in Treatment
of Sepsis in Ovine (Sheep) Model of the Disease
Doctor Perenlei Enkhbaatar is a member of the
Company’s board of directors. Under his leadership at the
University of Texas Galveston Medical Branch, sepsis was induced in
22 adult female Merino sheep by intravenous administration of the
gram-negative bacillus Pseudomonas aeruginosa. This infection model
produces a highly reproducible and rapidly lethal form of septic
shock that precisely mimics the clinical presentation in human
patients of cytokine storm, acute lung injury, loss of vascular
tone, severe oxidant stress and multiple organ failure. Although
rodent models are useful in the study of novel therapies for
sepsis, the demonstration of efficacy in a large animal model, such
as in sheep, is more predictive of results in the human clinical
setting, and is a necessary step in the advancement of any novel
treatment for viral sepsis in man. A control group consisted of 13
sheep that were treated with an intramuscular injection of
saline.
The results of this study unequivocally
demonstrated that R-107 treatment reduced mortality, with 11%
mortality noted among those sheep treated with R-107 versus 30%
mortality observed among those sheep in the control group. R-107
therapy significantly decreased lung injury, eliminated oxidant
stress and preserved multi-organ function. There were no adverse
effects observed in response to R-107 treatment. Taken
together, the observations that R-107 is highly effective and safe
in this large animal model provide critical support for the
Company’s development of R-107 for COVID-19 related sepsis.
Sepsis is the Leading Cause of Death
Among COVID-19 Patients
Although most COVID-19 infections cause mild to
moderate illness with respiratory and flu-like symptoms, a
significant number of patients progress from these initial mild
symptoms to more serious and potentially fatal viral sepsis. In
COVID-19 viral sepsis, the body has a dysregulated immune response
to the COVID-19 virus, which causes severe oxidant stress and
life-threatening dysfunction in organs including the lungs, brain,
kidneys, heart, and liver. COVID-19 viral sepsis is the leading
cause of death among COVID-19 infected patients, with a mortality
rate in the range of 30% - 40%.3
Claritas is Will Develop R-107 for the
Treatment of COVID-19 Related Sepsis Based on the Significantly
Positive Data in Seen in the Ovine (Sheep) Model of
Sepsis
“The data reported in the Scientific Reports
article demonstrate that R-107 significantly reduced mortality in a
clinically-predictive animal model of sepsis. The importance of
these data cannot be overstated,” said Robert Farrell, Claritas’
President and CEO. “While bacterial sepsis may be treated with
antibiotics, this is not the case with COVID-19 viral sepsis.
Approved therapies, such as remdesivir, dexamethasone and
bamlanivimab, are helpful for patients with mild illness, but are
not particularly effective in COVID-19 patients who have developed
sepsis. For COVID-19 patients who have developed sepsis, there are
few available therapies beyond supportive care.”4
Mr. Farrell went on to state that, “Our data
unequivocally demonstrate that R-107 treatment reduced mortality in
a controlled study in a large animal model of sepsis. We are aware
of no other drug that is marketed or in development that has
achieved superior results in this animal model of the disease.”
The Company is not making any express or implied
claims that its product has the ability to eliminate, cure, or
contain the Covid-19 (or SARS-2 Coronavirus) at this time.
About Claritas
PharmaceuticalsClaritas Pharmaceuticals, Inc. is a
clinical stage biopharmaceutical company focused on developing and
commercializing therapies for patients with significant unmet
medical needs. Claritas leverages its expertise to find solutions
that will improve health outcomes and dramatically improve people's
lives.
- Website
Home: https://claritaspharma.com/
- News and
Insights: https://claritaspharma.com/news/
-
Investors: https://claritaspharma.com/investors
Cautionary StatementsNeither
TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
This press release may contain certain
forward-looking information and statements ("forward-looking
information") within the meaning of applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation in respect of its product candidate pipeline,
planned clinical trials, regulatory approval prospects,
intellectual property objectives, and other statements containing
the words "believes", "anticipates", "plans", "intends", "will",
"should", "expects", "continue", "estimate", "forecasts" and other
similar expressions. Readers are cautioned to not place undue
reliance on forward-looking information. Actual results and
developments may differ materially from those contemplated by these
statements depending on, among other things, the risk that future
clinical studies may not proceed as expected or may produce
unfavorable results. Claritas undertakes no obligation to comment
on analyses, expectations or statements made by third parties, its
securities, or financial or operating results (as applicable).
Although Claritas believes that the expectations reflected in
forward-looking information in this press release are reasonable,
such forward-looking information has been based on expectations,
factors and assumptions concerning future events which may prove to
be inaccurate and are subject to numerous risks and uncertainties,
certain of which are beyond Claritas’ control. The forward-looking
information contained in this press release is expressly qualified
by this cautionary statement and is made as of the date hereof.
Claritas disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise.
Contact InformationRobert
FarrellPresident, CEO(888) 861-2008info@claritaspharma.com
1 Health Leaders Media, Expert: Severe COVID-19 Illness is Viral
Sepsis, Christopher Cheney, November 25, 20202 Sepsis Treatment
Market To Reach Valuation Of US$ 1.6 Bn By 2031: Transparency
Market Research, April 8, 20213 Health Leaders Media, Expert:
Severe COVID-19 Illness is Viral Sepsis, Christopher Cheney,
November 25, 20204 Health Leaders Media, Expert: Severe COVID-19
Illness is Viral Sepsis, Christopher Cheney, November 25, 2020
Kalytera Therapeutics (TSXV:KLY)
Historical Stock Chart
From Nov 2024 to Dec 2024
Kalytera Therapeutics (TSXV:KLY)
Historical Stock Chart
From Dec 2023 to Dec 2024